Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 201-210 of 525 for center for individualized medicine

Edit search filters
  1. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  2. A Study to Evaluate MesilatE for Treating Hospitalized Patients with COVID-19 (Enrolling by Invitation Only)

    Jacksonville, FL, Scottsdale/Phoenix, AZ

  3. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  4. A Study of the Safety and Effectiveness of INC280 Alone and in Combination with Erlotinib, When Compared to Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutation and Amplified cMET

    Rochester, MN

  5. A Study of the Expression and Frequency of Tissue Biomarker Mutations in Breast Cancer that is Resistant or Refractory to Treatment with Trastuzumab and/or Pertuzumab

  6. Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas

    Jacksonville, FL, Rochester, MN

  8. (+) Epicatechin to Treat Friedreich's Ataxia

    Rochester, MN

  9. Gene Therapy and Radioactive Iodine in Treating Patients with Locally Recurrent Prostate Cancer that Did Not Respond to External-Beam Radiation Therapy

    Rochester, MN

  10. Impact of Estradiol Addback

    Rochester, MN

.

Mayo Clinic Footer